
The Myth of “Normal” in Women’s Health: Clue CEO Rhiannon White on Building a Business Around Women’s Real Needs
Dr. Dereck Mush, MD, MBAEmbla is a Copenhagen-based metabolic health company that pairs low-dose GLP-1 medication with behavioral coaching.
Embla delivers obesity care that combines low-dose GLP-1 medication, one-on-one behavioral coaching and structured tapering. It started as a direct-to-consumer clinic in Denmark and the UK and now partners with self-funded employers and health plans, including in the US. The company says its TRIM study of 2,694 real-world participants, published in Diabetes, Obesity and Metabolism, showed average weight loss of 16.7% over 64 weeks at less than half the typical semaglutide dose. Embla was founded in 2021 by cardiologist Dr. Nicholas Syhler, formerly digital health innovation lead at Novo Nordisk, and Laust Wilster Axelsen. The company had raised about 14 million euros in venture funding as of May 2024.
How Embla got here, step by step.
August 2023
Embla raised a 10 million euro Series A led by Seed Capital and Inovo.
May 2024
Embla says its TRIM study of 2,694 real-world participants, published in Diabetes, Obesity and Metabolism, showed average weight loss of 16.7% over 64 weeks at less than half the typical semaglutide dose.

Dr. Dereck Mush, MD, MBAMentions Embla
Related companies
Your daily HealthTech Signal
Get the latest HealthTech news, understand why it matters, and see where the industry is headed.



Read by teams at companies like: